Ascent Industries Reports Fourth Quarter and Full Year 2022 Results
Ascent Industries Co. (Nasdaq: ACNT) reported significant financial results for Q4 and the full year 2022, showing a 23.7% increase in net sales, totaling $414.1 million. Despite this growth, Q4 net income fell 98.4% to $0.1 million, and adjusted EBITDA decreased to negative $2.0 million. The gross profit margin also dipped to 2.0% in Q4, down from 20.8% in Q4 2021. The company aims to enhance profitability by reducing operations at its unprofitable Munhall facility, focusing on specialty chemicals, which grew 59% in net sales for the year.
- Full year net sales increased by 23.7% to $414.1 million.
- Net income for the full year rose by 9.0% to $22.1 million.
- Ascent Chemicals segment grew by 59% in net sales for 2022.
- Q4 net income dropped by 98.4% to $0.1 million.
- Adjusted EBITDA for Q4 was negative $2.0 million.
- Gross profit margin fell to 2.0% in Q4, down from 20.8% year-over-year.
Insights
Analyzing...
Second Consecutive Year of Growth in
Ascent Chemicals Continues to Outperform with Year-Over-Year Growth in
Fourth Quarter Net Income of
Fourth Quarter 2022 Summary
(in millions, expect per share and margin) |
Q4 2022 |
Q4 2021 |
Change |
|
|
|
- |
Gross Profit |
|
|
- |
Gross Profit Margin |
|
|
-1880bps |
Net Income |
|
|
- |
Diluted Earnings per Share |
|
|
- |
Adjusted EBITDA |
|
|
- |
Adjusted EBITDA Margin |
(2.4)% |
|
-1790bps |
Full Year 2022 Summary
(in millions, except per share and margin) |
2022 |
2021 |
Change |
|
|
|
|
Gross Profit |
|
|
- |
Gross Profit Margin |
|
|
-450bps |
Net Income |
|
|
|
Diluted Earnings per share |
|
|
- |
Adjusted EBITDA |
|
|
- |
Adjusted EBITDA Margin |
|
|
-450bps |
________________________________ |
1 Company management has previously articulated its intent to reduce operations at the Company's facility in |
Management Commentary
“Although we certainly faced some challenges during the last two quarters of the year, I don’t want that to take away from the progress we made throughout 2022 towards operational excellence,” said
“As expected, specific items within our tubular products segment negatively impacted our consolidated financial results to close out the year. That said, the bulk of the financial issues were contained to our
“Ascent Chemicals remained a stalwart during the fourth quarter with year-over-year growth across the top line and a minimal decline in the bottom line as the pricing environment continued to stabilize. We are pleased with the overall profile of this segment given its stable customer base and high margin, recurring revenue that we believe can provide a solid base for us to meaningfully grow over the long-term. Our sales pipeline for Ascent Chemicals in 2023 remains strong, and we believe the foundation we have built more easily allows us to incorporate adjacent products and new offerings as the broader M&A landscape begins to open up. We believe that our specialty chemicals segment has significant long-term growth potential, and we are confident in the ability of our team to seize these opportunities.
“Overall, we believe we are on a path toward sustained profitable growth over the long-term. To achieve this, we will focus on providing best-in-class products and services, investing in technology and automation to improve efficiencies, and pursuing strategic acquisitions within the specialty chemicals segment that meet our return thresholds. Our dedicated team remains steadfast in their commitment to delivering long-term value to our shareholders through a culture of hard work and performance-based results.”
Fourth Quarter 2022 Financial Results
Net sales were
Gross profit was
Net income was
Adjusted EBITDA was
Full Year 2022 Financial Results
Net sales increased
Gross profit was
Net income increased
Adjusted EBITDA was
Segment Results
Ascent Tubular – net sales in the fourth quarter of 2022 were
Net sales in 2022 increased
Ascent Chemicals – net sales in the fourth quarter of 2022 increased
Net sales in 2022 increased
Liquidity
As of
For the year ended
Conference Call
Ascent will conduct a conference call today at
Ascent management will host the conference call, followed by a question and answer period.
Date:
Time:
Live Call Registration Link: Here
Webcast Registration Link: Here
To access the call by phone, please register via the live call registration link above or here and you will be provided with dial-in instructions and details. If you have any difficulty connecting with the conference call, please contact
The conference call will also be broadcast live and available for replay via the webcast registration link above or here. The webcast will be archived for one year in the investor relations section of the Company’s website at www.ascentco.com.
About
Forward-Looking Statements
This press release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. All statements that are not historical facts are forward-looking statements. Forward looking statements can be identified through the use of words such as "estimate," "project," "intend," "expect," "believe," "should," "anticipate," "hope," "optimistic," "plan," "outlook," "should," "could," "may" and similar expressions. The forward-looking statements are subject to certain risks and uncertainties which could cause actual results to differ materially from historical results or those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements and to review the risks as set forth in more detail in Ascent Industries Co.’s
Non-GAAP Financial Information
Financial statement information included in this earnings release includes non-GAAP (Generally Accepted Accounting Principles) measures and should be read along with the accompanying tables which provide a reconciliation of non-GAAP measures to GAAP measures.
Adjusted EBITDA is a non-GAAP financial measure that the Company believes is useful to investors in evaluating its results to determine the value of a company. An item is excluded in the measure if its periodic value is inconsistent and sufficiently material that not identifying the item would render period comparability less meaningful to the reader or if including the item provides a clearer representation of normalized periodic earnings. The Company excludes in Adjusted EBITDA two categories of items: 1) Base EBITDA components, including: interest expense (including change in fair value of interest rate swap), income taxes, depreciation and amortization, and 2) Material transaction costs including: goodwill impairment, asset impairment, gain on lease modification, stock-based compensation, non-cash lease cost, acquisition costs and other fees, proxy contest costs and recoveries, shelf registration costs, loss on extinguishment of debt, earn-out adjustments, realized and unrealized (gains) and losses on investments in equity securities and other investments, retention costs and restructuring & severance costs from net income.
Management believes that these non-GAAP measures are useful because they are key measures used by our management team to evaluate our operating performance, generate future operating plans and make strategic decisions as well as allow readers to compare the financial results between periods. Non-GAAP measures should not be considered as an alternative to any measure of performance or financial condition as promulgated under GAAP, and investors should consider the Company's performance and financial condition as reported under GAAP and all other relevant information when assessing the performance or financial condition of the Company. Non-GAAP measures have limitations as analytical tools, and investors should not consider them in isolation or as a substitute for analysis of the Company's results or financial condition as reported under GAAP.
Condensed Consolidated Balance Sheets ($ in thousands) |
|||||||
|
|
|
|
||||
|
|
|
|
||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
1,441 |
|
|
$ |
2,021 |
|
Accounts receivable, net of allowance for credit losses of |
|
45,120 |
|
|
|
50,126 |
|
Inventories, net |
|
114,452 |
|
|
|
103,249 |
|
Prepaid expenses and other current assets |
|
8,982 |
|
|
|
3,728 |
|
Assets held for sale |
|
380 |
|
|
|
855 |
|
Total current assets |
|
170,375 |
|
|
|
159,979 |
|
Property, plant and equipment, net |
|
42,346 |
|
|
|
43,720 |
|
Right-of-use assets, operating leases, net |
|
29,224 |
|
|
|
30,811 |
|
|
|
11,389 |
|
|
|
12,637 |
|
Intangible assets, net |
|
10,387 |
|
|
|
14,382 |
|
Deferred income taxes |
|
1,353 |
|
|
|
— |
|
Deferred charges, net |
|
203 |
|
|
|
302 |
|
Other non-current assets, net |
|
3,766 |
|
|
|
4,171 |
|
Total assets |
$ |
269,043 |
|
|
$ |
266,002 |
|
|
|
|
|
||||
Liabilities and Shareholders' Equity |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
22,731 |
|
|
$ |
32,318 |
|
Accounts payable - related parties |
|
— |
|
|
|
2 |
|
Accrued expenses and other current liabilities |
|
6,560 |
|
|
|
12,407 |
|
Current portion of note payable |
|
387 |
|
|
|
— |
|
Current portion of long-term debt |
|
2,464 |
|
|
|
2,464 |
|
Current portion of earn-out liabilities |
|
— |
|
|
|
1,961 |
|
Current portion of operating lease liabilities |
|
1,056 |
|
|
|
1,104 |
|
Current portion of finance lease liabilities |
|
280 |
|
|
|
233 |
|
Total current liabilities |
|
33,478 |
|
|
|
50,489 |
|
Long-term debt |
|
69,085 |
|
|
|
67,928 |
|
Long-term portion of operating lease liabilities |
|
30,911 |
|
|
|
32,059 |
|
Long-term portion of finance lease liabilities |
|
1,242 |
|
|
|
1,414 |
|
Deferred income taxes |
|
— |
|
|
|
2,433 |
|
Other long-term liabilities |
|
68 |
|
|
|
89 |
|
Total non-current liabilities |
|
101,306 |
|
|
|
103,923 |
|
|
|
|
|
||||
Commitments and contingencies |
|
|
|
||||
|
|
|
|
||||
Shareholders' equity: |
|
|
|
||||
Common stock, par value |
|
11,085 |
|
|
|
11,085 |
|
Capital in excess of par value |
|
47,021 |
|
|
|
46,058 |
|
Retained earnings |
|
85,146 |
|
|
|
63,080 |
|
|
|
143,252 |
|
|
|
120,223 |
|
Less: cost of common stock in treasury - 924,504 and 918,471 shares, respectively |
|
(8,993 |
) |
|
|
(8,633 |
) |
Total shareholders' equity |
|
134,259 |
|
|
|
111,590 |
|
Total liabilities and shareholders' equity |
$ |
269,043 |
|
|
$ |
266,002 |
|
Note: The condensed consolidated balance sheets at |
Condensed Consolidated Statements of Income - Comparative Analysis (Unaudited) ($ in thousands, except per share data) |
|||||||||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Net sales |
|
|
|
|
|
|
|
||||||||
Tubular Products |
$ |
58,087 |
|
|
$ |
73,799 |
|
|
$ |
306,605 |
|
|
$ |
267,238 |
|
Specialty Chemicals |
|
23,473 |
|
|
|
21,868 |
|
|
|
107,542 |
|
|
|
67,477 |
|
|
$ |
81,560 |
|
|
$ |
95,667 |
|
|
$ |
414,147 |
|
|
$ |
334,715 |
|
Operating income (loss) |
|
|
|
|
|
|
|||||||||
Tubular Products |
$ |
(4,323 |
) |
|
$ |
11,767 |
|
|
$ |
27,607 |
|
|
$ |
33,561 |
|
Specialty Chemicals |
|
860 |
|
|
|
1,658 |
|
|
|
6,971 |
|
|
|
3,656 |
|
|
|
|
|
|
|
|
|
||||||||
Corporate |
|
|
|
|
|
|
|
||||||||
Unallocated corporate expenses |
|
(2,761 |
) |
|
|
(1,690 |
) |
|
|
(12,997 |
) |
|
|
(6,828 |
) |
Acquisition costs and other |
|
(363 |
) |
|
|
(800 |
) |
|
|
(1,200 |
) |
|
|
(1,001 |
) |
Proxy contest costs and recoveries |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(168 |
) |
Earn-out adjustments |
|
— |
|
|
|
(442 |
) |
|
|
7 |
|
|
|
(1,872 |
) |
Total Corporate |
|
(3,124 |
) |
|
|
(2,932 |
) |
|
|
(14,190 |
) |
|
|
(9,869 |
) |
Operating income (loss) |
|
(6,587 |
) |
|
|
10,493 |
|
|
|
20,388 |
|
|
|
27,348 |
|
Interest expense |
|
1,104 |
|
|
|
418 |
|
|
|
2,742 |
|
|
|
1,486 |
|
Loss on extinguishment of debt |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
223 |
|
Change in fair value of interest rate swap |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2 |
) |
Other, net |
|
(34 |
) |
|
|
(10 |
) |
|
|
(209 |
) |
|
|
143 |
|
Income (loss) before income taxes |
|
(7,657 |
) |
|
|
10,085 |
|
|
|
17,855 |
|
|
|
25,498 |
|
Income tax provision (benefit) |
|
(7,784 |
) |
|
|
2,018 |
|
|
|
(4,211 |
) |
|
|
5,253 |
|
Net income |
$ |
127 |
|
|
$ |
8,067 |
|
|
$ |
22,066 |
|
|
$ |
20,245 |
|
|
|
|
|
|
|
|
|
||||||||
Net income per common share |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
0.01 |
|
|
$ |
0.85 |
|
|
$ |
2.16 |
|
|
$ |
2.17 |
|
Diluted |
$ |
0.01 |
|
|
$ |
0.84 |
|
|
$ |
2.12 |
|
|
$ |
2.14 |
|
|
|
|
|
|
|
|
|
||||||||
Average shares outstanding |
|
|
|
|
|
|
|
||||||||
Basic |
|
10,213 |
|
|
|
9,518 |
|
|
|
10,230 |
|
|
|
9,340 |
|
Diluted |
|
10,416 |
|
|
|
9,617 |
|
|
|
10,410 |
|
|
|
9,456 |
|
|
|
|
|
|
|
|
|
||||||||
Other data: |
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA1 |
$ |
(1,964 |
) |
|
$ |
14,861 |
|
|
$ |
36,021 |
|
|
$ |
44,308 |
|
1The term Adjusted EBITDA is a non-GAAP financial measure that the Company believes is useful to investors in evaluating its results to determine the value of a company. An item is excluded in the measure if its periodic value is inconsistent and sufficiently material that not identifying the item would render period comparability less meaningful to the reader or if including the item provides a clearer representation of normalized periodic earnings. The Company excludes in Adjusted EBITDA two categories of items: 1) Base EBITDA components, including: interest expense (including change in fair value of interest rate swap), income taxes, depreciation and amortization, and 2) Material transaction costs including: goodwill impairment, asset impairment, gain on lease modification, stock-based compensation, non-cash lease cost, acquisition costs and other fees, proxy contest costs and recoveries, loss on extinguishment of debt, earn-out adjustments, realized and unrealized (gains) and losses on investments in equity securities and other investments, retention costs and restructuring & severance costs from net income. For a reconciliation of this non-GAAP measure to the most comparable GAAP equivalent, refer to the Reconciliation of Net Income (Loss) to Adjusted EBITDA. |
Consolidated Statements of Cash Flows (Unaudited) ($ in thousands) |
|||||||
|
Year Ended |
||||||
|
|
2022 |
|
|
|
2021 |
|
Operating activities |
|
|
|
||||
Net income |
$ |
22,066 |
|
|
$ |
20,245 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
||||
Depreciation expense |
|
8,722 |
|
|
|
7,547 |
|
Amortization expense |
|
3,995 |
|
|
|
2,794 |
|
Amortization of debt issuance costs |
|
99 |
|
|
|
95 |
|
Asset impairments |
|
— |
|
|
|
233 |
|
Loss on extinguishment of debt |
|
— |
|
|
|
223 |
|
Deferred income taxes |
|
(4,211 |
) |
|
|
(2,071 |
) |
Earn-out adjustments |
|
(7 |
) |
|
|
1,872 |
|
Payments of earn-out liabilities in excess of acquisition date fair value |
|
(662 |
) |
|
|
(138 |
) |
Provision for (reduction of) losses on accounts receivable |
|
1,034 |
|
|
|
(398 |
) |
Provision for losses on inventories |
|
3,052 |
|
|
|
1,649 |
|
Loss (gain) on disposal of property, plant and equipment |
|
27 |
|
|
|
(848 |
) |
Non-cash lease expense |
|
414 |
|
|
|
481 |
|
Non-cash lease termination loss |
|
— |
|
|
|
5 |
|
Change in fair value of interest rate swap |
|
— |
|
|
|
(2 |
) |
Payments for termination of interest rate swap |
|
— |
|
|
|
(46 |
) |
Issuance of treasury stock for director fees |
|
364 |
|
|
|
132 |
|
Stock-based compensation expense |
|
1,407 |
|
|
|
799 |
|
Changes in operating assets and liabilities: |
|
|
|
||||
Accounts receivable |
|
3,972 |
|
|
|
(16,185 |
) |
Inventories |
|
(13,779 |
) |
|
|
(18,873 |
) |
Other assets and liabilities |
|
(12 |
) |
|
|
(55 |
) |
Accounts payable |
|
(10,277 |
) |
|
|
10,835 |
|
Accounts payable - related parties |
|
(2 |
) |
|
|
2 |
|
Accrued expenses |
|
(2,702 |
) |
|
|
1,506 |
|
Accrued income taxes |
|
(7,923 |
) |
|
|
9,253 |
|
Net cash provided by operating activities |
|
5,577 |
|
|
|
19,055 |
|
Investing activities |
|
|
|
||||
Purchases of property, plant and equipment |
|
(5,074 |
) |
|
|
(1,497 |
) |
Proceeds from disposal of property, plant and equipment |
|
99 |
|
|
|
1,400 |
|
Acquisitions, net of cash acquired |
|
— |
|
|
|
(32,564 |
) |
Net cash (used in) provided by investing activities |
|
(4,975 |
) |
|
|
(32,661 |
) |
Financing activities |
|
|
|
||||
Borrowings from long-term debt |
|
443,363 |
|
|
|
215,528 |
|
Proceeds from note payable |
|
967 |
|
|
|
— |
|
Proceeds from the issuance of common stock related to Rights Offering |
|
— |
|
|
|
10,010 |
|
Proceeds from the exercise of stock options |
|
175 |
|
|
|
109 |
|
Payments on long-term debt |
|
(442,206 |
) |
|
|
(206,505 |
) |
Payments on note payable |
|
(580 |
) |
|
|
— |
|
Principal payments on finance lease obligations |
|
(266 |
) |
|
|
(92 |
) |
Payments on earn-out liabilities |
|
(1,292 |
) |
|
|
(3,494 |
) |
Repurchase of common stock |
|
(1,343 |
) |
|
|
— |
|
Payments for deferred financing costs |
|
— |
|
|
|
(165 |
) |
Net cash used in financing activities |
|
(1,182 |
) |
|
|
15,391 |
|
(Decrease) increase in cash and cash equivalents |
|
(580 |
) |
|
|
1,785 |
|
Cash and cash equivalents, beginning of period |
|
2,021 |
|
|
|
236 |
|
Cash and cash equivalents, end of period |
$ |
1,441 |
$ |
2,021 |
Non-GAAP Financial Measures Reconciliation Reconciliation of Net Income to Adjusted EBITDA (Unaudited) ($ in thousands) |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
($ in thousands) |
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Consolidated |
|
|
|
|
|
|
|
||||||||
Net income |
$ |
127 |
|
|
$ |
8,067 |
|
|
$ |
22,066 |
|
|
$ |
20,245 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Interest expense |
|
1,104 |
|
|
|
418 |
|
|
|
2,742 |
|
|
|
1,486 |
|
Change in fair value of interest rate swap |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2 |
) |
Income taxes |
|
(7,784 |
) |
|
|
2,018 |
|
|
|
(4,211 |
) |
|
|
5,253 |
|
Depreciation |
|
2,343 |
|
|
|
2,088 |
|
|
|
8,722 |
|
|
|
7,547 |
|
Amortization |
|
1,407 |
|
|
|
754 |
|
|
|
3,995 |
|
|
|
2,794 |
|
EBITDA |
|
(2,803 |
) |
|
|
13,345 |
|
|
|
33,314 |
|
|
|
37,323 |
|
Acquisition costs and other |
|
363 |
|
|
|
800 |
|
|
|
1,200 |
|
|
|
1,001 |
|
Proxy contest costs and recoveries1 |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
168 |
|
Shelf registration costs |
|
12 |
|
|
|
— |
|
|
|
12 |
|
|
|
— |
|
Loss on extinguishment of debt |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
223 |
|
Earn-out adjustments |
|
— |
|
|
|
442 |
|
|
|
(7 |
) |
|
|
1,872 |
|
Loss on investment in equity securities and other investments |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
363 |
|
Asset impairments |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
233 |
|
Gain on lease modification |
|
— |
|
|
|
— |
|
|
|
(2 |
) |
|
|
— |
|
Stock-based compensation |
|
308 |
|
|
|
103 |
|
|
|
1,016 |
|
|
|
799 |
|
Non-cash lease expense |
|
92 |
|
|
|
108 |
|
|
|
414 |
|
|
|
481 |
|
Retention expense |
|
— |
|
|
|
6 |
|
|
|
— |
|
|
|
500 |
|
Restructuring and severance costs |
|
64 |
|
|
|
57 |
|
|
|
74 |
|
|
|
1,345 |
|
Adjusted EBITDA |
$ |
(1,964 |
) |
|
$ |
14,861 |
|
|
$ |
36,021 |
|
|
$ |
44,308 |
|
% sales |
|
(2.4 |
)% |
|
|
15.5 |
% |
|
|
8.7 |
% |
|
|
13.2 |
% |
1Proxy contest costs and recoveries for the year months ended |
Non-GAAP Financial Measures Reconciliation Reconciliation of Net Income to Adjusted EBITDA (Unaudited) ($ in thousands) |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
($ in thousands) |
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Tubular Products |
|
|
|
|
|
|
|
||||||||
Net income (loss) |
$ |
(4,392 |
) |
|
$ |
11,335 |
|
|
$ |
27,644 |
|
|
$ |
31,893 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Interest expense |
|
— |
|
|
|
— |
|
|
|
1 |
|
|
|
— |
|
Depreciation expense |
|
1,375 |
|
|
|
1,293 |
|
|
|
4,814 |
|
|
|
5,485 |
|
Amortization expense |
|
1,217 |
|
|
|
680 |
|
|
|
3,092 |
|
|
|
2,721 |
|
EBITDA |
|
(1,800 |
) |
|
|
13,308 |
|
|
|
35,551 |
|
|
|
40,099 |
|
Acquisition costs and other |
|
96 |
|
|
|
— |
|
|
|
96 |
|
|
|
— |
|
Earn-out adjustments |
|
— |
|
|
|
442 |
|
|
|
(7 |
) |
|
|
1,872 |
|
Stock-based compensation |
|
36 |
|
|
|
54 |
|
|
|
100 |
|
|
|
129 |
|
Retention expense |
|
— |
|
|
|
6 |
|
|
|
— |
|
|
|
500 |
|
Restructuring and severance costs |
|
20 |
|
|
|
— |
|
|
|
20 |
|
|
|
363 |
|
Tubular Products Adjusted EBITDA |
$ |
(1,648 |
) |
|
$ |
13,810 |
|
|
$ |
35,760 |
|
|
$ |
42,963 |
|
% segment sales |
|
(2.8 |
)% |
|
|
18.7 |
% |
|
|
11.7 |
% |
|
|
16.1 |
% |
|
|
|
|
|
|
|
|
||||||||
Specialty Chemicals |
|
|
|
|
|
|
|
||||||||
Net income |
$ |
852 |
|
|
$ |
1,588 |
|
|
$ |
6,935 |
|
|
$ |
3,589 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Interest expense |
|
9 |
|
|
|
9 |
|
|
|
36 |
|
|
|
11 |
|
Depreciation expense |
|
949 |
|
|
|
768 |
|
|
|
3,846 |
|
|
|
1,932 |
|
Amortization expense |
|
191 |
|
|
|
73 |
|
|
|
903 |
|
|
|
73 |
|
EBITDA |
|
2,001 |
|
|
|
2,438 |
|
|
|
11,720 |
|
|
|
5,605 |
|
Acquisition costs and other |
|
— |
|
|
|
61 |
|
|
|
— |
|
|
|
61 |
|
Asset impairments |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
233 |
|
Stock-based compensation |
|
12 |
|
|
|
(8 |
) |
|
|
41 |
|
|
|
165 |
|
Non-cash lease expense |
|
— |
|
|
|
— |
|
|
|
2 |
|
|
|
— |
|
Restructuring and severance costs |
|
8 |
|
|
|
57 |
|
|
|
8 |
|
|
|
484 |
|
Specialty Chemicals Adjusted EBITDA |
$ |
2,021 |
|
|
$ |
2,548 |
|
|
$ |
11,771 |
|
|
$ |
6,548 |
|
% segment sales |
|
8.6 |
% |
|
|
11.7 |
% |
|
|
10.9 |
% |
|
|
9.7 |
% |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005095/en/
Company Contact
Chief Financial Officer
1-630-884-9181
Investor Relations
1-949-574-3860
ACNT@gatewayir.com
Source: